| Year |
Citation |
Score |
| 2022 |
Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, Tran PT. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. European Urology Oncology. PMID 36283936 DOI: 10.1016/j.euo.2022.09.007 |
0.312 |
|
| 2022 |
Christensen M, Hannan R. The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. Cancers. 14. PMID 36230615 DOI: 10.3390/cancers14194693 |
0.346 |
|
| 2022 |
Montalvo SK, Meng B, Lin MH, Park C, Desai NB, Hannan R, Garant A. Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer. Frontiers in Oncology. 12: 898822. PMID 36046047 DOI: 10.3389/fonc.2022.898822 |
0.332 |
|
| 2022 |
Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, Lotan Y, Timmerman RD, Garant A, ... Hannan R, et al. Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Frontiers in Oncology. 12: 779182. PMID 35265519 DOI: 10.3389/fonc.2022.779182 |
0.304 |
|
| 2021 |
Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D, Garant A, Arafat W, Courtney K, Bowman I, Cole S, Sher D, Ahn C, Choy H, Timmerman R, et al. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. European Urology Oncology. PMID 34986993 DOI: 10.1016/j.euo.2021.12.001 |
0.336 |
|
| 2021 |
Hannan R, Salamekh S, Desai NB, Garant A, Folkert MR, Costa DN, Mannala S, Ahn C, Mohamad O, Laine A, Kim DWN, Dickinson T, Raj GV, Shah RB, Wang J, et al. Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 34774676 DOI: 10.1016/j.ijrobp.2021.10.137 |
0.312 |
|
| 2021 |
Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, ... ... Hannan R, et al. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. Advances in Radiation Oncology. 6: 100692. PMID 34646963 DOI: 10.1016/j.adro.2021.100692 |
0.325 |
|
| 2021 |
Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Şanli Ö, Garant A, Bagrodia A, Margulis V, Lotan Y, Hannan R, Desai N, Woldu SL. Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. Urologic Oncology. PMID 34215505 DOI: 10.1016/j.urolonc.2021.05.005 |
0.306 |
|
| 2021 |
Folkert MR, Zelefsky MJ, Hannan R, Desai NB, Lotan Y, Laine AM, Kim DWN, Neufeld SH, Hornberger B, Kollmeier MA, McBride S, Ahn C, Roehrborn C, Timmerman RD. A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. International Journal of Radiation Oncology, Biology, Physics. PMID 33753140 DOI: 10.1016/j.ijrobp.2021.03.025 |
0.301 |
|
| 2020 |
Dohopolski M, Hannan R, Wardak Z, Hammers H, Garant A. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer. Cancer Journal (Sudbury, Mass.). 26: 448-459. PMID 32947313 DOI: 10.1097/Ppo.0000000000000475 |
0.455 |
|
| 2020 |
Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Seminars in Radiation Oncology. 30: 129-138. PMID 32381292 DOI: 10.1016/J.Semradonc.2019.12.009 |
0.336 |
|
| 2020 |
Lu T, Wang S, Xu L, Zhou Q, Singla N, Gao J, Manna S, Pop L, Xie Z, Chen M, Luke JJ, Brugarolas J, Hannan R, Wang T. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology. 5. PMID 32086382 DOI: 10.1126/Sciimmunol.Aaz3199 |
0.331 |
|
| 2020 |
Desai NB, Folkert MR, Leiker A, Yan Y, Costa DN, Dess RT, Spratt DE, Garant A, Hannan R, Timmerman RD. Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): A phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps381 |
0.398 |
|
| 2020 |
Chen L, Gao A, Gannavarapu BS, Garant A, Desai NB, Folkert MR, Ahn C, Roehrborn CG, Lotan Y, Timmerman RD, Hannan R. Safety and outcome of stereotactic body radiation therapy (SBRT) with rectal hydrogel spacer for prostate cancer. Journal of Clinical Oncology. 38: 76-76. DOI: 10.1200/Jco.2020.38.6_Suppl.76 |
0.438 |
|
| 2020 |
Elias R, Levonyak N, Christie A, Bowman IA, Kapur P, Hannan R, Hammers HJ, Brugarolas J. A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38: 647-647. DOI: 10.1200/Jco.2020.38.6_Suppl.647 |
0.322 |
|
| 2020 |
Hammers HJ, Vonmerveldt D, Ahn C, Nadal RM, Drake CG, Folkert MR, Laine AM, Courtney KD, Brugarolas J, Song DY, Hannan R, Carducci MA. Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). Journal of Clinical Oncology. 38: 614-614. DOI: 10.1200/Jco.2020.38.6_Suppl.614 |
0.361 |
|
| 2020 |
Sandler HM, Karrison T, Sartor AO, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto M, Pervez N, Balogh AG, Rodrigues G, Souhami L, Reaume MN, Williams S, Hannan R, et al. Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521. Journal of Clinical Oncology. 38: 333-333. DOI: 10.1200/Jco.2020.38.6_Suppl.333 |
0.33 |
|
| 2020 |
Freifeld Y, Israel H, Pedrosa I, Mcloughlin M, Correa R, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo R, Porta C, Bucknell NW, Siva S, Brugarolas J, ... ... Hannan R, et al. Mp14-12 Stereotactic Ablative Radiation Therapy (Sabr) For Treatment Of Renal Cell Carcinoma (Rcc) With Inferior Vena Cava Tumor Thrombus (Ivc-Tt) The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000839.012 |
0.415 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Brugarolas J, ... ... Hannan R, et al. Stereotactic Ablative Radiotherapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31377159 DOI: 10.1016/J.Ijrobp.2019.07.023 |
0.409 |
|
| 2019 |
Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus. PMID 31248849 DOI: 10.1016/J.Euf.2019.06.002 |
0.336 |
|
| 2019 |
Atluri PS, Gannavarapu BS, Timmerman RD, Garant A, Hannan R, Folkert MR, Desai NB. Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer. Practical Radiation Oncology. PMID 31173917 DOI: 10.1016/J.Ijrobp.2019.06.890 |
0.352 |
|
| 2019 |
Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, et al. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802158. PMID 30860948 DOI: 10.1200/Jco.18.02158 |
0.408 |
|
| 2019 |
Elias R, Yan F, Singla N, Levonyack N, Formella J, Christie A, Kapur P, Bowman AI, Hammers HJ, Hannan R, Brugarolas J. Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients. Journal of Clinical Oncology. 37: 645-645. DOI: 10.1200/Jco.2019.37.7_Suppl.645 |
0.319 |
|
| 2019 |
Zhang Y, Schoenhals J, Christie A, Wang C, Mohamad O, Singla N, Desai N, Choy H, Courtney KD, Bagrodia A, Margulis V, Bowman IA, Timmerman RD, Brugarolas J, Hannan R. Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer. Journal of Clinical Oncology. 37: 599-599. DOI: 10.1200/Jco.2019.37.7_Suppl.599 |
0.391 |
|
| 2019 |
Ramani V, Chung J, Kobayashi M, Schoenhals J, Cruz PD, Hannan R, Ariizumi K. DC-HIL/Gpnmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E14129 |
0.39 |
|
| 2019 |
Elias RM, Singla N, Bowman IA, Kapur P, Hannan R, Hammers H, Brugarolas J. Abstract 4106: Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study Cancer Research. 79: 4106-4106. DOI: 10.1158/1538-7445.Sabcs18-4106 |
0.399 |
|
| 2019 |
Gannavarapu B, Rezaeian NH, Folkert M, Hannan R, Garant A, Timmerman R, Hrycushko B, Desai N. Focal Salvage High Dose Rate (HDR) Brachytherapy after Neurovascular-Sparing Prostate Stereotactic Ablative Radiation Therapy (SAbR): A Pilot Dosimetric Study International Journal of Radiation Oncology*Biology*Physics. 105: E703. DOI: 10.1016/J.Ijrobp.2019.06.957 |
0.427 |
|
| 2019 |
Pop LM, Manna S, Christley S, Freifeld Y, Vo DT, Filatenkov A, Kapur P, Monson N, Pedrosa I, Brugarolas J, Timmerman RD, Margulis V, Cowell LG, Hannan R. Immune Correlates of Abscopal Response in a Lead-in Phase II Trial of Neoadjuvant Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.430 |
0.34 |
|
| 2019 |
Schoenhals J, Mohamad O, Christie A, Garant A, Desai NB, Bowman I, Courtney K, Hammers H, Timmerman RD, Brugarolas J, Hannan R. Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Renal Cell Carcinoma International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1957 |
0.345 |
|
| 2019 |
Li D, Christie A, Bowman I, Brugarolas J, Hannan R. Safety of Concurrent Hypofractionated Radiation Therapy and Systemic Therapy for Renal Cell Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1953 |
0.424 |
|
| 2019 |
Manna S, Mulgaonkar A, Woolford L, Nham K, Hao G, Pop LM, Bowman I, Brugarolas J, Sun X, Hannan R. Immuno-PET Evaluation of In Vivo Therapeutic Resistance in Renal Cell Carcinoma Patient-Derived Xenografts International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1064 |
0.302 |
|
| 2018 |
Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, et al. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. European Urology Oncology. 1: 276-282. PMID 31100248 DOI: 10.1016/J.Euo.2018.04.014 |
0.428 |
|
| 2018 |
Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi L, Barnett S, Patel T, Mickey B, Whitworth T, Hannan R, Brugarolas J, Timmerman R. Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. Clinical Genitourinary Cancer. PMID 30595522 DOI: 10.1016/J.Clgc.2018.11.006 |
0.358 |
|
| 2018 |
Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, et al. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clinical Genitourinary Cancer. PMID 30538068 DOI: 10.1016/J.Clgc.2018.11.007 |
0.374 |
|
| 2018 |
Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer. PMID 30217763 DOI: 10.1016/J.Clgc.2018.08.001 |
0.391 |
|
| 2018 |
Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, ... ... Hannan R, et al. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology. 7: e1440168. PMID 29900043 DOI: 10.1080/2162402X.2018.1440168 |
0.314 |
|
| 2018 |
Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, et al. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discovery. PMID 29884728 DOI: 10.1158/2159-8290.Cd-17-1246 |
0.312 |
|
| 2018 |
Bowman IA, Bent A, Le T, Christie A, Wardak Z, Mickey B, Timmerman RD, Hannan R, Brugarolas J. Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches. Journal of Clinical Oncology. 36: 601-601. DOI: 10.1200/Jco.2018.36.6_Suppl.601 |
0.355 |
|
| 2018 |
Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld YN, Sanli ON, Krabbe L, Hutchinson RC, Lotan Y, Hammers HJ, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study. Journal of Clinical Oncology. 36: 586-586. DOI: 10.1200/Jco.2018.36.6_Suppl.586 |
0.389 |
|
| 2018 |
Woldu S, Matulay J, Clinton T, Singla N, Freifeld Y, Sanli O, Krabbe L, Hutchinson R, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V. Pd24-04 Incidence And Outcomes Of Delayed Targeted Therapy Following Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1197 |
0.372 |
|
| 2018 |
Leiker AJ, Rezaeian NH, Laine AM, Hannan R, Folkert MR, Timmerman RD, Jia X, Desai NB. Prostate Cancer Neurovascular Element Sparing with Stereotactic Ablative Radiation Therapy (SAbR): A Pilot Dosimetric Study for the POTEN-C Trial International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.335 |
0.437 |
|
| 2018 |
Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck B, George A, Kaffenberger S, Salami S, Hearn JWD, Jolly S, Morgan TM, et al. Prostate Cancer-Specific Mortality Following Salvage Post-Prostatectomy Radiation Therapy: A Competition Between Age and Time to Biochemical Failure International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.324 |
0.43 |
|
| 2017 |
Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DWN, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman RD, Folkert MR. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists. PMID 28774760 DOI: 10.1016/J.Meddos.2017.07.002 |
0.409 |
|
| 2017 |
Chi Y, Rezaeian NH, Shen C, Zhou Y, Lu W, Yang M, Hannan R, Jia X. A new method to reconstruct intra-fractional prostate motion in volumetric modulated arc therapy. Physics in Medicine and Biology. 62: 5509-5530. PMID 28609300 DOI: 10.1088/1361-6560/Aa6E37 |
0.321 |
|
| 2017 |
Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, ... ... Hannan R, et al. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. International Journal of Radiation Oncology, Biology, Physics. 98: 91-100. PMID 28587057 DOI: 10.1016/J.Ijrobp.2017.01.032 |
0.42 |
|
| 2017 |
Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB. Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study. Bju International. PMID 28581200 DOI: 10.1111/Bju.13926 |
0.432 |
|
| 2017 |
Jackson WC, Desai N, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, et al. Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-Prostatectomy Salvage Radiation Therapy: A Multi-Institutional Study. Bju International. PMID 28139024 DOI: 10.1111/Bju.13792 |
0.412 |
|
| 2017 |
Folkert MR, Zelefsky MJ, Hannan R, Desai NB, Lotan Y, Laine AM, Kim DWN, Hardee S, Hornberger B, Kollmeier MA, McBride S, Xie XJ, Roehrborn C, Timmerman RD. Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 99: 1319-1320. DOI: 10.1016/J.Ijrobp.2017.09.020 |
0.436 |
|
| 2017 |
Mohamad O, Leiker A, Schroeder S, Zhang E, Trivedi L, Gerber D, Khan S, Iyengar P, Albuquerque K, Arriaga Y, Courtney K, Brugarolas J, Hammers H, Timmerman R, Hannan R. Safety and Outcomes of Combining Immune Checkpoint Inhibitors with Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 99: E610-E611. DOI: 10.1016/J.Ijrobp.2017.06.2071 |
0.359 |
|
| 2017 |
Wang CJ, Christi A, Bowman IA, Xie XJ, Laine AM, Desai NB, Timmerman RD, Brugarolas J, Hannan R. Stereotactic Ablative Radiotherapy Prolongs Surveillance and Delays Initiation of Systemic Therapy in Patients with Renal Cancer Metastases International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1255 |
0.415 |
|
| 2017 |
Jones RT, Desai NB, Rezaeian NH, Folkert MR, Timmerman RD, Hannan R. Dose Constraints for the Bladder and Urethra for Stereotactic Body Radiation Therapy to the Prostate International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1186 |
0.423 |
|
| 2016 |
Hassan Rezaeian N, Chi Y, Zhou Y, Tian Z, Jiang S, Hannan R, Jia X. TH-CD-207A-12: Impacts of Inter- and Intra-Fractional Organ Motion for High-Risk Prostate Cancer Stereotactic Body Radiation Therapy. Medical Physics. 43: 3882. PMID 28047620 DOI: 10.1118/1.4958181 |
0.408 |
|
| 2016 |
Rezaeian NH, Chi Y, Tian Z, Jiang S, Hannan R, Jia X. SU-G-BRA-12: Development of An Intra-Fractional Motion Tracking and Dose Reconstruction System for Adaptive Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer. Medical Physics. 43: 3637-3638. PMID 28046869 DOI: 10.1118/1.4956936 |
0.411 |
|
| 2016 |
Chi Y, Rezaeian NH, Hannan R, Jia X. SU-G-JeP1-02: A New Intra-Fractional Prostate Motion Tracking Method in Volumetric Modulated Arc Therapy (VMAT) Via 2D/3D Registration. Medical Physics. 43: 3648. PMID 28046218 DOI: 10.1118/1.4956977 |
0.342 |
|
| 2016 |
Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R. Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy : Cii. PMID 27743027 DOI: 10.1007/S00262-016-1914-6 |
0.385 |
|
| 2016 |
Ishihara D, Louder K, Akter M, Ahn C, Margulis V, Arriaga Y, Courtney K, Timmerman RD, Brugarolas J, Hannan R. Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)-Interim Analysis of i-SAbR IL-2 Trial. International Journal of Radiation Oncology, Biology, Physics. 96: S96-S97. PMID 27676061 DOI: 10.1016/J.Ijrobp.2016.06.241 |
0.352 |
|
| 2016 |
Maquilan G, Westover KD, Wardak Z, Timmerman RD, Hannan R, Iyengar P, Schwartz DL, Meyer JJ, Abdulrahman RE, Folkert MR, Laine AM, Desai NB, Albuquerque KV, Choy H, Ahn C, et al. Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease. International Journal of Radiation Oncology, Biology, Physics. 96: E527. PMID 27674929 DOI: 10.1016/J.Ijrobp.2016.06.1949 |
0.346 |
|
| 2016 |
Tumati V, Spratt DE, Jackson WC, Feng FY, Roehrborn C, Lotan Y, Pistenmaa DA, Laine AM, Folkert MR, Hannan R, Desai NB. Natural History of Progression After Biochemical Failure Following Postoperative Radiation Therapy in Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E239. PMID 27674145 DOI: 10.1016/J.Ijrobp.2016.06.1224 |
0.449 |
|
| 2016 |
Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R. Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proceedings of the National Academy of Sciences of the United States of America. PMID 27651484 DOI: 10.1073/Pnas.1613187113 |
0.319 |
|
| 2016 |
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. European Journal of Cancer (Oxford, England : 1990). 59: 142-151. PMID 27035363 DOI: 10.1016/J.Ejca.2016.02.014 |
0.425 |
|
| 2016 |
Wang CJ, Cai X, Kim DW, Huelsmann L, Meyer JJ, Pedrosa I, Brugarolas J, Margulis V, Timmerman RD, Hannan R. The effect of stereotactic ablative radiotherapy on time to change of systemic therapy in extra-cranial renal cell carcinoma metastases. Journal of Clinical Oncology. 34: 533-533. DOI: 10.1200/Jco.2016.34.2_Suppl.533 |
0.412 |
|
| 2016 |
Hannan R, Ishihara D, Louder K, Ahn C, Margulis V, Arriaga YE, Courtney KD, Timmerman RD, Brugarolas J. Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis. Journal of Clinical Oncology. 34: 532-532. DOI: 10.1200/Jco.2016.34.2_Suppl.532 |
0.316 |
|
| 2016 |
Tumati V, Jacobs C, Ying J, Roehrborn CG, Lotan Y, Margulis V, Pistenmaa DA, Kim DW, Hannan R. Outcomes in patients with high-risk prostate cancer treated with definitive versus adjuvant radiation therapy. Journal of Clinical Oncology. 34: 133-133. DOI: 10.1200/Jco.2016.34.2_Suppl.133 |
0.454 |
|
| 2016 |
Jacobs C, Tumati V, Kapur P, Hannan R, Hsieh J, Kim DW, Saha D. Association of decreased tumor DAB2IP and high-risk prostate cancer-specific survival. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16553 |
0.38 |
|
| 2015 |
Hu C, Rosenthal SA, Sartor O, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto M, Pervez N, Balogh AG, Rodrigues G, Souhami L, Reaume MN, Williams SG, Hannan R, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: LBA5002. PMID 28147726 DOI: 10.1200/Jco.2015.33.18_Suppl.Lba5002 |
0.44 |
|
| 2015 |
Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D. Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. Cancer Medicine. PMID 26471467 DOI: 10.1002/Cam4.554 |
0.44 |
|
| 2015 |
Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R. A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Annals of Surgical Oncology. PMID 25963478 DOI: 10.1245/S10434-015-4579-Z |
0.323 |
|
| 2015 |
Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Choy H, Brugarolas J, Timmerman RD. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biology & Therapy. 16: 657-61. PMID 25800036 DOI: 10.1080/15384047.2015.1026506 |
0.451 |
|
| 2015 |
Ying J, Tumati V, Yan J, Xie XJ, Roehrborn C, Margulis V, Pistenmaa DA, Hannan R, Choe KS, Kim DWN. High Presalvage Radiation Therapy Prostate-Specific Antigen Strongly Correlates With Very Early Failure, Which Leads to Worse Outcome International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1106 |
0.41 |
|
| 2015 |
Wang CJ, Huelsmann L, Hannan R, Timmerman RD, Meyer JJ, Abdulrahman RE, Nedzi LA, Margulis V, Brugarolas J, Kim DWN. Extracranial Renal Cell Carcinoma Treated With Stereotactic Ablative Body Radiation Therapy Leads to Excellent Lesional Control International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1069 |
0.387 |
|
| 2015 |
Ishihara D, Iyengar P, Meyer J, Timmerman R, Choy H, Hannan R. The combination of radiation therapy and immunotherapy for genitourinary cancer treatment: rationale, current evidence, and prospects Journal of Radiation Oncology. 4: 355-363. DOI: 10.1007/S13566-015-0233-4 |
0.416 |
|
| 2014 |
Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma. Clinical Genitourinary Cancer. PMID 25620636 DOI: 10.1016/J.Clgc.2014.12.007 |
0.307 |
|
| 2014 |
Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. Practical Radiation Oncology. 4: 409-14. PMID 25407863 DOI: 10.1016/J.Prro.2014.01.002 |
0.408 |
|
| 2014 |
Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn CG, Choe KS, Kim DW. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biology & Therapy. 15: 699-706. PMID 24658086 DOI: 10.4161/Cbt.28554 |
0.452 |
|
| 2014 |
Chun SG, Jacobs CD, Yan J, Xie X, Choe KS, Hannan R, Pistenmaa DA, Lotan Y, Roehrborn CG, Kim DW. The effects of anticoagulant use in high-risk prostate cancer treated with radiotherapy on overall survival and biochemical control. Journal of Clinical Oncology. 32: 146-146. DOI: 10.1200/Jco.2014.32.4_Suppl.146 |
0.431 |
|
| 2014 |
Takeshima T, Vitetta E, Hannan R. Anti-tumor characteristics of radiation-induced tumor-infiltrating neutrophils Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P162 |
0.313 |
|
| 2014 |
Gao D, Bhuiyan M, Yu L, Takeshima T, Hannan R, Hsieh J, Saha D, Kim D. Suppression of Radiation-Induced c-Met Activation Leads to Radiosensitization of Prostate Cancer Cells International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.683 |
0.403 |
|
| 2014 |
Kim D, Bhuiyan M, Toffesi-Tcheuyup V, Pavia-Jimenez A, Holloman E, Huelsmann L, Gao D, Hannan R, Chen B, Saha D, Brugarolas J. Validated Tumor Graft Model Reveals Delayed Local Recurrence of Renal Cell Tumors After High-Dose Single Fraction Ablative Radiation Therapy International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.2314 |
0.395 |
|
| 2012 |
Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, Guha C. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunology, Immunotherapy : Cii. 61: 2227-38. PMID 22644735 DOI: 10.1007/S00262-012-1257-X |
0.385 |
|
| 2012 |
Hannan R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen CC, Landau E, Miller E, Spierer M, Hong L, Kalnicki S. Hypofractionated whole-breast radiation therapy: does breast size matter? International Journal of Radiation Oncology, Biology, Physics. 84: 894-901. PMID 22543209 DOI: 10.1016/J.Ijrobp.2012.01.093 |
0.335 |
|
| 2012 |
Yaparpalvi R, Hannan R, Landau E, Kahan N, Bodner W, Kuo HC, Minsky L, Mehta KJ, Garg MK, Kalnicki S, Guha C. Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implants. Brachytherapy. 11: 489-94. PMID 21868289 DOI: 10.1016/J.Brachy.2011.07.004 |
0.341 |
|
| 2012 |
Kim D, Tumati V, Pistenmaa D, Kapur P, Xie X, Hannan R, Jacobs C, Straka C, Hsieh J, Saha D. Loss of Tumor Suppressor DAB2IP Correlates With Decreased Biochemical Recurrence-free Survival in High-Risk Prostate Cancer Patients Treated With Radiation Therapy International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1912 |
0.455 |
|
| 2012 |
Kabarriti R, Hannan R, Baliga S, Kalnicki S, Guha C, Garg M. Predictive Value of PSA Trend During and After Postprostatectomy Salvage Radiation Therapy International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.1079 |
0.384 |
|
| 2011 |
Blakaj D, Fox JL, Manzerova J, Hannan R, Hong L, Mehta KJ, Kalnicki S. Toxicity of hypofractionated adjuvant radiation after breast-conserving surgery for DCIS. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 128. PMID 27958174 DOI: 10.1200/Jco.2011.29.27_Suppl.128 |
0.33 |
|
| 2011 |
Hannan R, Shan J, Gandhi S, Bernstein K, Blakaj D, Montagna C, Tong T, Kalnicki S, Garg M, Guha C. TMPRSS2-ERG Loci Abnormality in Salvage Radiation Therapy (sRT) Refractory Prostate Cancer Patients International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.1169 |
0.454 |
|
| 2010 |
Hannan R, Rossinow J, Chen Y, Kabarri R, Skinner W, Landau EM, Spierer M, Guha C, Kalnicki S, Garg M. PSA trend before and during salvage radiation therapy: Prognostic factor for biochemical control. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E15048 |
0.419 |
|
| 2010 |
Thompson RF, Spierer M, Hannan R, Chen Y, Kabarriti R, Skinner W, Chen C, Miller E, Hong L, Kalnicki S. Poster Viewing AbstractHypofractionated Whole Breast Radiation Therapy: Does Size Matter? International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.529 |
0.339 |
|
| 2010 |
Hannan R, Cohen P, Lu L, Zhang H, Saha S, Kabarriti R, Alfieri A, Garg M, Kalnicki S, Guha C. A Novel Combination of Listeria PSA Vaccine and Radiation Therapy for Prostate Cancer (PC) International Journal of Radiation Oncology*Biology*Physics. 78: S642-S643. DOI: 10.1016/J.Ijrobp.2010.07.1496 |
0.413 |
|
| 2009 |
Hannan R, Spierer M, Skinner W, Kabarriti R, Chen C, Bernstein K, Landau E, Miller E, Hong L, Kalnicki S. Hypofractionated Whole Breast Radiation Therapy for Large-breasted Patients International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.516 |
0.307 |
|
| 2008 |
Thawani N, Vainshtein JM, Hannan R, Kalnicki S, Yaparpalvi R, Mutyala S. Comparison of intensity modulated radiation therapy (IMRT) with conventional radiotherapy (CRT) for cervical cancer with concurrent cisplatin (CDDP) Journal of Clinical Oncology. 26: 5562-5562. DOI: 10.1200/Jco.2008.26.15_Suppl.5562 |
0.414 |
|
| 2008 |
Vainshtein J, Mutyala S, Thawani N, Hannan R, Yaparpalvi R, Kalnicki S. Comparison of Intensity Modulated Radiation Therapy (IMRT) with Conventional Radiotherapy (CRT) for Treatment of Uterine Papillary Serous Carcinoma (UPSC) with Sequential Carboplatin and Paclitaxel Chemotherapy: A Toxicity Study International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.1201 |
0.41 |
|
| 2008 |
Mutyala S, Thawani N, Vainshtein JM, Hannan R, Saigal K, Mehta KJ, Shah SJ, Spierer MM, Yaparpalvi R, Kalnicki S. Dose Constraint Recommendations and a Predictive Nomogram of Incidence of Hematological Toxicity for Cervix Cancer Patients Treated with Concurrent Cisplatin and Intensity Modulated Radiation Therapy (IMRT) International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.1189 |
0.422 |
|
| 2003 |
Topper RQ, Chung K, Boelke CM, Louie D, Kang JS, Hannan R, Kiang T, Chan LH. Computational structural determination and energy landscape analysis of the hepatic carcinogen 2-(acetylamino)fluorene Theoretical Chemistry Accounts. 109: 233-238. DOI: 10.1007/S00214-002-0409-Z |
0.611 |
|
| Show low-probability matches. |
